Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist

Submitted by admin on November 4, 2024 - 11:13am
Source: 
Fierce Biotech
News Tags: 
Novo Nordisk
Ascendis Pharma
biobucks
drug development
Headline: 
Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist
snippet: 

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Do Not Allow Advertisers to Use My Personal information